1. Field of the Invention
The present invention relates generally to blood clotting devices and, more particularly, to blood clotting materials, devices incorporating such materials, and methods for the delivery of such materials for use as bleeding control devices.
2. Description of the Related Art
Blood is a liquid tissue that includes red cells, white cells, corpuscles, and platelets dispersed in a liquid phase. The liquid phase is plasma, which includes acids, lipids, solublized electrolytes, and proteins. The proteins are suspended in the liquid phase and can be separated out of the liquid phase by any of a variety of methods such as filtration, centrifugation, electrophoresis, and immunochemical techniques. One particular protein suspended in the liquid phase is fibrinogen. When bleeding occurs, the fibrinogen reacts with water and thrombin (an enzyme) to form fibrin, which is insoluble in blood and polymerizes to form clots.
In a wide variety of circumstances, animals, including humans, can be wounded. Often bleeding is associated with such wounds. In some circumstances, the wound and the bleeding are minor, and normal blood clotting functions in addition to the application of simple first aid are all that is required. Unfortunately, however, in other circumstances substantial bleeding can occur. These situations usually require specialized equipment and materials as well as personnel trained to administer appropriate aid. If such aid is not readily available, excessive blood loss can occur. When bleeding is severe, sometimes the immediate availability of equipment and trained personnel is still insufficient to stanch the flow of blood in a timely manner.
Moreover, severe wounds can often be inflicted in remote areas or in situations, such as on a battlefield, where adequate medical assistance is not immediately available. In these instances, it is important to stop bleeding, even in less severe wounds, long enough to allow the injured person or animal to receive medical attention.
In an effort to address the above-described problems, materials have been developed for controlling excessive bleeding in situations where conventional aid is unavailable or less than optimally effective. Although these materials have been shown to be somewhat successful, they are sometimes not effective enough for traumatic wounds and tend to be expensive. Furthermore, these materials are sometimes ineffective in some situations and can be difficult to apply as well as remove from a wound.
Additionally, or alternatively, the previously developed materials can produce undesirable side effects. For example, prior art blood clotting material is generally a powder or a fine particulate in which the surface area of the material often produces an exothermic reaction upon the application of the material to blood. Oftentimes excess material is unnecessarily poured onto a wound, which can exacerbate the exothermic effects. Depending upon the specific attributes of the material, the resulting exothermia may be sufficient to cause discomfort to or even burn the patient. Although some prior art patents specifically recite the resulting exothermia as being a desirable feature that can provide clotting effects to the wound that are similar to cauterization, there exists the possibility that the tissue at and around the wound site may be undesirably impacted.
Furthermore, to remove such materials from wounds, irrigation of the wound is often required. If an amount of material is administered that causes discomfort or burning, the wound may require immediate flushing. In instances where a wounded person or animal has not yet been transported to a facility capable of providing the needed irrigation, undesirable effects or over-treatment of the wound may result.
Bleeding can also be a problem during surgical procedures. Apart from suturing or stapling an incision or internally bleeding area, bleeding is often controlled using a sponge or other material used to exert pressure against the bleed site and/or absorb the blood. However, when the bleeding becomes excessive, these measures may not be sufficient to stop the flow of blood. Moreover, any highly exothermic bleed-control material may damage the tissue surrounding the bleed site and may not be configured for easy removal after use.
Based on the foregoing, it is a general object of the present invention to provide devices for controlling bleeding and methods of their use that overcome or improve upon the prior art.
According to one aspect, the present invention resides in an apparatus for promoting the clotting of blood, thereby controlling bleeding. The apparatus comprises a receptacle for retaining molecular sieve material in particulate form therein. At least a portion of the receptacle is defined by a mesh having openings therein such that when the apparatus is applied to a bleed site, the particulate molecular sieve material comes into contact with blood through the openings.
Other aspects of the present invention include a pad for controlling bleeding and a bandage applicable to a bleeding wound. In both the pad and the bandage, there is a mesh structure and particles of molecular sieve material retained therein. In the pad embodiment, there is a rigid or semi-rigid support attached to the mesh structure to facilitate the application of pressure to the pad and the wound. In the bandage, there is a flexible substrate attached to the mesh structure, the substrate being a cloth or plastic member that may be adhesively attached to cover a wound. In any embodiment, the mesh structure may be defined by a plurality of members (strands, filaments, or strips of synthetic or natural material) interconnected and arranged to define openings. The openings are sized to allow contact to be maintained between the particles of the molecular sieve material and blood.
In yet another aspect of the present invention, a method of dressing a bleeding wound includes providing a molecular sieve material in particle form and retaining the material in a mesh structure, placing the mesh structure on a bleeding wound such that the molecular sieve material comes into contact with blood flowing from the wound, applying pressure to the mesh structure to ensure contact of the material with the blood, and removing the mesh structure from the wound.
An advantage of the present invention is that upon completion of the application of any of the devices of the present invention to a bleeding wound, the devices can be easily removed. In particular, because the zeolite material is in granule, bead, or pellet form and encased in a pouch or mesh structure, the material can be cleanly pulled away from the treated wound and disposed of. Accordingly, little or no irrigation of the wound is required to flush away remaining zeolite. In devices in which the pouch containing zeolite material is incorporated into an adhesive bandage, the device can be left on the wound for the amount of time necessary to cause clotting.
Another advantage is that the particlized form of the zeolite material allows the material to react less exothermically with blood. As the particle size increases (e.g., from fine to coarse), the surface area of the particles that the blood can come into contact with decreases. The porous nature of the material still allows liquid blood constituents to be wicked away to cause thickening of the blood, thereby facilitating the formation of clots. Because the particle surface area exposed to the blood is reduced, a less aggressive drawing of moisture from the blood is realized, which thereby tempers the exothermic effects experienced at the wound site.
Still another advantage of the present invention is that the proper dose of molecular sieve material can be readily applied to an open wound. Particularly when the device is a porous pouch containing zeolite material, the device can be readily removed from sterilized packaging and held directly at the points from which blood emanates to facilitate clotting of the blood without spilling powder or pellets outside the wound area. Guesswork, estimation, or calculation of the amounts of molecular sieve material for application to a bleeding wound is eliminated. Accordingly, little or no molecular sieve material is wasted.
Disclosed herein are devices and methods for delivering materials to wounds to promote the clotting of blood and the dressing of the wounds. The devices generally comprise expedients or apparatuses that can be applied to bleeding wounds such that the materials contact the tissue of the wound to minimize or stop a flow of blood by absorbing at least portions of the liquid phases of the blood, thereby promoting clotting. One apparatus comprises a receptacle for retaining molecular sieve material in particulate form therein. At least a portion of the receptacle is defined by a mesh having openings therein, and at least a portion of the particulate molecular sieve material is in direct contact with blood through the openings.
The molecular sieve material used in the present invention may be a synthetic polymer gel, cellulosic material, porous silica gel, porous glass, alumina, hydroxyapatite, calcium silicate, zirconia, zeolite, or the like. Exemplary synthetic polymers include, but are not limited to, stylene-divinylbenzene copolymer, cross-linked polyvinyl alcohol, cross-linked polyacrylate, cross-linked vinyl ether-maleic anhydride copolymer, cross-linked stylene-maleic anhydride copolymer or cross-linked polyamide, and combinations thereof.
The molecular sieve material is preferably a zeolite. Other molecular sieve materials that may be used include, but are not limited to, faujasite. As used herein, the term “zeolite” refers to a crystalline form of aluminosilicate having the ability to be dehydrated without experiencing significant changes in the crystalline structure. The zeolite may include one or more ionic species such as, for example, calcium and sodium moieties. Typically, the zeolite is a friable material that is about 90% by weight calcium and about 10% by weight sodium. The calcium portion contains crystals that are about 5 angstroms in size, and the sodium portion contains crystals that are about 4 angstroms in size. The preferred molecular structure of the zeolite is an “A-type” crystal, namely, one having a cubic crystalline structure that defines round or substantially round openings.
The zeolite may be mixed with or otherwise used in conjunction with other materials having the ability to be dehydrated without significant changes in crystalline structure. Such materials include, but are not limited to, magnesium sulfate, sodium metaphosphate, calcium chloride, dextrin, a polysaccharide, combinations of the foregoing materials, and hydrates of the foregoing materials.
Zeolites for use in the disclosed applications may be naturally occurring or synthetically produced. Numerous varieties of naturally occurring zeolites are found as deposits in sedimentary environments as well as in other places. Naturally occurring zeolites that may be applicable to the compositions described herein include, but are not limited to, analcite, chabazite, heulandite, natrolite, stilbite, and thomosonite. Synthetically produced zeolites that may also find use in the compositions and methods described herein are generally produced by processes in which rare earth oxides are substituted by silicates, alumina, or alumina in combination with alkali or alkaline earth metal oxides.
Various materials may be mixed with, associated with, or incorporated into the zeolites to maintain an antiseptic environment at the wound site or to provide functions that are supplemental to the clotting functions of the zeolites. Exemplary materials that can be used include, but are not limited to, pharmaceutically-active compositions such as antibiotics, antifungal agents, antimicrobial agents, anti-inflammatory agents, analgesics (e.g., cimetidine, chloropheniramine maleate, diphenhydramine hydrochloride, and promethazine hydrochloride), bacteriostatics, compounds containing silver ions, and the like. Other materials that can be incorporated to provide additional hemostatic functions include ascorbic acid, tranexamic acid, rutin, and thrombin. Botanical agents having desirable effects on the wound site may also be added.
In one embodiment of the present invention, a device for facilitating the clotting of blood directly at a wound site is shown with reference to
The zeolite particles 14 are substantially spherical or irregular in shape (e.g., balls, beads, pellets, or the like) and about 0.2 millimeters (mm) to about 10 mm in diameter, preferably about 1 mm to about 7 mm in diameter, and more preferably about 2 mm to about 5 mm in diameter. In any embodiment (balls, beads, pellets, etc.), less particle surface area is available to be contacted by blood as the particle size is increased. Therefore, the rate of clotting can be controlled by varying the particle size. Furthermore, the adsorption of moisture (which also has an effect on the exothermic effects of the zeolite) can also be controlled.
The mesh 12 is defined by interconnected strands, filaments, or strips of material. The strands, filaments, or strips can be interconnected in any one or a combination of manners including, but not limited to, being woven into a gauze, intertwined, integrally-formed, and the like. Preferably, the interconnection is such that the mesh can flex while substantially maintaining the dimensions of the openings defined thereby. The material from which the strands, filaments or strips are fabricated may be a polymer (e.g., nylon, polyethylene, polypropylene, polyester, or the like), metal, fiberglass, or an organic substance (e.g., cotton, wool, silk, or the like).
Referring now to
To apply the pouch 10 to a bleeding wound, the pouch is removed from the packaging and placed on the bleeding wound. The zeolite particles 14 in the mesh 12 contact the tissue of the wound and/or the blood, and at least a portion of the liquid phase of the blood is adsorbed by the zeolite material, thereby promoting the clotting of the blood.
Another embodiment of the present invention is a pad which is shown at 20 with reference to
The mesh 12 is stitched, glued, clamped, or otherwise mounted to the support 22. The support 22 comprises an undersurface 24 against which the zeolite particles 14 are held by the container 12 and a top surface 26. The undersurface 24 is impermeable to the zeolite particles 14 (migration of the particles into the support 22 is prevented) and is further resistant to the absorption of water or other fluids. The top surface 26 is capable of having a pressure exerted thereon by a person applying the pad 20 to a bleeding wound or by a weight supported on the top surface 26. The entire support 22 is rigid or semi-rigid so as to allow the application of pressure while minimizing discomfort to the patient.
To apply the pad 20 to a bleeding wound, the pad 20 is removed from its packaging and placed on the bleeding wound. As with the pouch of the embodiment of
Referring now to
The substrate 52 is a plastic or a cloth member that is conducive to being retained on the skin of an injured person or animal on or proximate a bleeding wound. An adhesive 54 is disposed on a surface of the substrate 52 that engages the skin of the injured person or animal. Particularly if the substrate 52 is a non-breathable plastic material, the substrate may include holes 56 to allow for the dissipation of moisture evaporating from the skin surface.
In the preparation of zeolite material for the devices of the present invention (i.e., formation of the material into particle form), an initial level of hydration of the zeolite may be controlled by the application of heat to the zeolite material either before or after the material is formed into particles. However, it has also surprisingly been found that as the particle size of the zeolite is increased, the moisture content has less of a correlative effect on any exothermia produced as the result of mixing the particlized zeolite in blood. As such, formation of the zeolite material into the zeolite particles (shown at 14 in
Although this invention has been shown and described with respect to the detailed embodiments thereof, it will be understood by those of skill in the art that various changes may be made and equivalents may be substituted for elements thereof without departing from the scope of the invention. In addition, modifications may be made to adapt a particular situation or material to the teachings of the invention without departing from the essential scope thereof. Therefore, it is intended that the invention not be limited to the particular embodiments disclosed in the above detailed description, but that the invention will include all embodiments falling within the scope of the appended claims.
This application is a continuation of U.S. patent application Ser. No. 11/054,918, filed Feb. 9, 2005, which is incorporated by references in its entirety herein.
Number | Name | Date | Kind |
---|---|---|---|
2688586 | Eberl et al. | Sep 1954 | A |
2969145 | Hannuer, Jr. | Jan 1961 | A |
3122140 | Crowe et al. | Feb 1964 | A |
3181231 | Breck | May 1965 | A |
3189227 | Hobbs et al. | Jun 1965 | A |
3366578 | Michalko | Jan 1968 | A |
3386802 | Michalko | Jun 1968 | A |
3538508 | Young | Nov 1970 | A |
3550593 | Kaufman | Dec 1970 | A |
3723352 | Warner et al. | Mar 1973 | A |
3979335 | Golovko et al. | Sep 1976 | A |
4373519 | Errede et al. | Feb 1983 | A |
4374044 | Schaefer et al. | Feb 1983 | A |
4379143 | Sherry et al. | Apr 1983 | A |
4435512 | Ito et al. | Mar 1984 | A |
4460642 | Errede et al. | Jul 1984 | A |
4514510 | Alexander | Apr 1985 | A |
4524064 | Nambu | Jun 1985 | A |
4525410 | Hagiwara et al. | Jun 1985 | A |
4569343 | Kimura et al. | Feb 1986 | A |
4626550 | Hertzenberg | Dec 1986 | A |
4631845 | Samuel et al. | Dec 1986 | A |
4651725 | Kifune et al. | Mar 1987 | A |
4748978 | Kamp | Jun 1988 | A |
4822349 | Hursey et al. | Apr 1989 | A |
4828081 | Nordstrom et al. | May 1989 | A |
4911898 | Hagiwara et al. | Mar 1990 | A |
4938958 | Niira et al. | Jul 1990 | A |
4956350 | Mosbey | Sep 1990 | A |
5140949 | Chu et al. | Aug 1992 | A |
5146932 | McCabe | Sep 1992 | A |
5474545 | Chikazawa | Dec 1995 | A |
5486195 | Myers et al. | Jan 1996 | A |
5538500 | Peterson | Jul 1996 | A |
5556699 | Niira et al. | Sep 1996 | A |
5578022 | Scherson et al. | Nov 1996 | A |
5597581 | Kaessmann et al. | Jan 1997 | A |
5599578 | Butland | Feb 1997 | A |
D386002 | Hinkle | Nov 1997 | S |
5696101 | Wu et al. | Dec 1997 | A |
5716337 | McCabe et al. | Feb 1998 | A |
5725551 | Myers et al. | Mar 1998 | A |
5728451 | Langley et al. | Mar 1998 | A |
5766715 | Garconnet | Jun 1998 | A |
5788682 | Maget | Aug 1998 | A |
5801116 | Cottrell et al. | Sep 1998 | A |
5826543 | Raymond et al. | Oct 1998 | A |
5855570 | Scherson et al. | Jan 1999 | A |
5916511 | Kotani et al. | Jun 1999 | A |
5941897 | Myers | Aug 1999 | A |
5964349 | Odagiri | Oct 1999 | A |
5981052 | Siguyama | Nov 1999 | A |
5993964 | Nakajima | Nov 1999 | A |
6037280 | Edwards et al. | Mar 2000 | A |
6060461 | Drake | May 2000 | A |
6086970 | Ren | Jul 2000 | A |
6123925 | Barry et al. | Sep 2000 | A |
6159232 | Nowakowski | Dec 2000 | A |
6187347 | Patterson et al. | Feb 2001 | B1 |
6203512 | Farris et al. | Mar 2001 | B1 |
6372333 | Sugiyama et al. | Apr 2002 | B1 |
6428800 | Greenspan et al. | Aug 2002 | B2 |
6450537 | Norris | Sep 2002 | B2 |
6475470 | Kayane et al. | Nov 2002 | B1 |
6481134 | Aledo | Nov 2002 | B1 |
6486285 | Fujita | Nov 2002 | B2 |
6495367 | Isogawa et al. | Dec 2002 | B1 |
6523778 | Key et al. | Feb 2003 | B2 |
6573419 | Naimer | Jun 2003 | B2 |
6590337 | Nishikawa et al. | Jul 2003 | B1 |
6622856 | Gallo et al. | Sep 2003 | B2 |
6630140 | Grunstein | Oct 2003 | B1 |
6685227 | Merry et al. | Feb 2004 | B2 |
6700032 | Gray | Mar 2004 | B1 |
6701649 | Brosi | Mar 2004 | B1 |
6745720 | Rasner et al. | Jun 2004 | B2 |
6998510 | Buckman et al. | Feb 2006 | B2 |
7125821 | Xu et al. | Oct 2006 | B2 |
7371403 | McCarthy et al. | May 2008 | B2 |
7429252 | Sarangapani | Sep 2008 | B2 |
7595429 | Hursey | Sep 2009 | B2 |
7604819 | Huey et al. | Oct 2009 | B2 |
7825133 | Yi | Nov 2010 | B2 |
7858123 | Stucky | Dec 2010 | B2 |
7968114 | Huey et al. | Jun 2011 | B2 |
8063264 | Spearman et al. | Nov 2011 | B2 |
8114433 | Huey et al. | Feb 2012 | B2 |
20020077653 | Hudson et al. | Jun 2002 | A1 |
20020197302 | Cochrum et al. | Dec 2002 | A1 |
20030133990 | Hursey et al. | Jul 2003 | A1 |
20030175333 | Shefer et al. | Sep 2003 | A1 |
20030176828 | Buckman et al. | Sep 2003 | A1 |
20030199922 | Buckman | Oct 2003 | A1 |
20030208150 | Bruder et al. | Nov 2003 | A1 |
20030212357 | Pace | Nov 2003 | A1 |
20040005350 | Looney et al. | Jan 2004 | A1 |
20040038893 | Ladner et al. | Feb 2004 | A1 |
20040166172 | Rosati et al. | Aug 2004 | A1 |
20040169033 | Kuibira et al. | Sep 2004 | A1 |
20040243043 | McCarthy et al. | Dec 2004 | A1 |
20050023956 | Kwak et al. | Feb 2005 | A1 |
20050058721 | Hursey | Mar 2005 | A1 |
20050070693 | Hansen et al. | Mar 2005 | A1 |
20050074505 | Hursey | Apr 2005 | A1 |
20050107826 | Zhu et al. | May 2005 | A1 |
20050118230 | Hill et al. | Jun 2005 | A1 |
20050119112 | Pfenninger et al. | Jun 2005 | A1 |
20050137512 | Campbell et al. | Jun 2005 | A1 |
20050143689 | Ramsey, III | Jun 2005 | A1 |
20050246009 | Toner et al. | Nov 2005 | A1 |
20050248270 | Ghosh et al. | Nov 2005 | A1 |
20050249899 | Bonutti | Nov 2005 | A1 |
20060034935 | Pronovost et al. | Feb 2006 | A1 |
20060078628 | Koman et al. | Apr 2006 | A1 |
20060116635 | Van Heughten | Jun 2006 | A1 |
20060121101 | Ladizinsky | Jun 2006 | A1 |
20060141018 | Cochrum et al. | Jun 2006 | A1 |
20060141060 | Hursey et al. | Jun 2006 | A1 |
20060159733 | Pendharkar et al. | Jul 2006 | A1 |
20060172000 | Cullen et al. | Aug 2006 | A1 |
20060178609 | Horn et al. | Aug 2006 | A1 |
20060193905 | Ehringer et al. | Aug 2006 | A1 |
20060211965 | Horn et al. | Sep 2006 | A1 |
20060211971 | Horn et al. | Sep 2006 | A1 |
20060271094 | Hudson et al. | Nov 2006 | A1 |
20060282046 | Horn et al. | Dec 2006 | A1 |
20070016152 | Karpowicz et al. | Jan 2007 | A1 |
20070031515 | Stucky et al. | Feb 2007 | A1 |
20070065491 | Huey et al. | Mar 2007 | A1 |
20070104768 | Huey et al. | May 2007 | A1 |
20070104792 | Jenkins | May 2007 | A1 |
20070134293 | Huey et al. | Jun 2007 | A1 |
20070142783 | Huey et al. | Jun 2007 | A1 |
20070154509 | Wilcher et al. | Jul 2007 | A1 |
20070154510 | Wilcher et al. | Jul 2007 | A1 |
20070154564 | Stucky et al. | Jul 2007 | A1 |
20070160638 | Mentkow et al. | Jul 2007 | A1 |
20070160653 | Fischer et al. | Jul 2007 | A1 |
20070167971 | Huey et al. | Jul 2007 | A1 |
20070251849 | Lo et al. | Nov 2007 | A1 |
20070275073 | Huey et al. | Nov 2007 | A1 |
20070276308 | Huey et al. | Nov 2007 | A1 |
20070276345 | Huey et al. | Nov 2007 | A1 |
20070281011 | Jenkins et al. | Dec 2007 | A1 |
20080027365 | Huey | Jan 2008 | A1 |
20080085300 | Huey et al. | Apr 2008 | A1 |
20080097271 | Lo et al. | Apr 2008 | A1 |
20080125686 | Lo | May 2008 | A1 |
20080146984 | Campbell et al. | Jun 2008 | A1 |
20080199539 | Baker et al. | Aug 2008 | A1 |
20080206134 | Lo et al. | Aug 2008 | A1 |
20080254146 | Huey et al. | Oct 2008 | A1 |
20080254147 | Huey et al. | Oct 2008 | A1 |
20080269658 | Vinton et al. | Oct 2008 | A1 |
20080299226 | Mentkow et al. | Dec 2008 | A1 |
20080317831 | Lo | Dec 2008 | A1 |
20080319476 | Ward et al. | Dec 2008 | A1 |
20090008261 | Kotzeva et al. | Jan 2009 | A1 |
20090043268 | Eddy et al. | Feb 2009 | A1 |
20090047366 | Bedard et al. | Feb 2009 | A1 |
20090053288 | Eskridge, Jr. et al. | Feb 2009 | A1 |
20090074880 | Ladizinsky | Mar 2009 | A1 |
20090076475 | Ross et al. | Mar 2009 | A1 |
20090112170 | Wells et al. | Apr 2009 | A1 |
20090162406 | Basadonna et al. | Jun 2009 | A1 |
20090186013 | Stucky | Jul 2009 | A1 |
20090186071 | Huey et al. | Jul 2009 | A1 |
20090232902 | Liu et al. | Sep 2009 | A1 |
20090299253 | Hursey | Dec 2009 | A1 |
20100035045 | McAmish | Feb 2010 | A1 |
20100121244 | Horn et al. | May 2010 | A1 |
20100209531 | Stucky et al. | Aug 2010 | A2 |
20100228174 | Huey et al. | Sep 2010 | A1 |
20100233248 | Huey et al. | Sep 2010 | A1 |
20110015565 | Hursey | Jan 2011 | A1 |
20110064785 | Daniels | Mar 2011 | A1 |
20110268784 | Huey | Nov 2011 | A1 |
20120004636 | Lo | Jan 2012 | A1 |
20120070470 | Pahari | Mar 2012 | A1 |
Number | Date | Country |
---|---|---|
1223208 | Jun 1987 | CA |
1970090 | May 2007 | CN |
101104080 | Jan 2008 | CN |
1114984 | Mar 2008 | CN |
101541274 | Sep 2009 | CN |
101687056 | Mar 2010 | CN |
0 107 051 | Sep 1983 | EP |
0 296 324 | Dec 1988 | EP |
0 353 710 | Feb 1990 | EP |
0 826 822 | Mar 1998 | EP |
0 888 783 | Jul 1999 | EP |
1 159 972 | May 2001 | EP |
1 663 090 | Jun 2006 | EP |
1 690 553 | Aug 2006 | EP |
1 714 642 | Oct 2006 | EP |
1 810 697 | Jul 2007 | EP |
1 679 087 | Jan 2010 | EP |
2 142 220 | Jan 2010 | EP |
1 667 623 | Nov 2010 | EP |
2 077 811 | Nov 2010 | EP |
2 292 196 | Mar 2011 | EP |
2 314 842 | Jan 1998 | GB |
2259858 | Aug 1999 | GB |
2 462 228 | Feb 2010 | GB |
1135892 | Jun 2010 | HK |
7088DELNP2009 | Apr 2008 | IN |
241410 | Jul 2010 | IN |
61145120 | Jul 1986 | JP |
01-096558 | Oct 1987 | JP |
2-45040 | Feb 1990 | JP |
9-504719 | May 1997 | JP |
2777279 | Jul 1998 | JP |
10-337302 | Dec 1998 | JP |
11-178912 | Jul 1999 | JP |
11-332909 | Jul 1999 | JP |
2002-530157 | Sep 2002 | JP |
2003-66045 | Mar 2003 | JP |
2004123651 | Jul 2006 | JP |
2011 00164 | Sep 2004 | TR |
WO 9505445 | Feb 1995 | WO |
WO 9512371 | May 1995 | WO |
WO 9640285 | Dec 1996 | WO |
WO 9913918 | Mar 1999 | WO |
WO 0030694 | Jun 2000 | WO |
WO 0066086 | Nov 2000 | WO |
WO 0182896 | Aug 2001 | WO |
WO 0197826 | Dec 2001 | WO |
WO 0230479 | Apr 2002 | WO |
WO 02060367 | Aug 2002 | WO |
WO 02074325 | Sep 2002 | WO |
WO 03074566 | Sep 2003 | WO |
WO 2005012493 | Feb 2005 | WO |
WO 2005027808 | Mar 2005 | WO |
WO 2005030279 | Apr 2005 | WO |
WO 2005087280 | Sep 2005 | WO |
WO 2005123170 | Dec 2005 | WO |
WO 2006012218 | Feb 2006 | WO |
WO 2006086557 | Aug 2006 | WO |
WO 2006088912 | Aug 2006 | WO |
WO 2006102008 | Sep 2006 | WO |
WO 2006110393 | Oct 2006 | WO |
WO 2007120342 | Oct 2007 | WO |
WO 2008036225 | Mar 2008 | WO |
WO 2008054566 | May 2008 | WO |
WO 2008109160 | Sep 2008 | WO |
WO 2008127497 | Oct 2008 | WO |
WO 2008128149 | Oct 2008 | WO |
WO 2008136806 | Nov 2008 | WO |
WO 2008157536 | Dec 2008 | WO |
WO 2009032884 | Mar 2009 | WO |
WO 2009126917 | Oct 2009 | WO |
Number | Date | Country | |
---|---|---|---|
20100121244 A1 | May 2010 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 11054918 | Feb 2005 | US |
Child | 12555876 | US |